Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18161889 | 0.97 | CXCR4 (0.40) | CXCR4ALDH1A1SMN1; SMN2CHRNA7HRH3 | |
| SCHEMBL63693 | 0.95 | CXCR4 (0.35) | CXCR4ALDH1A1SMN1; SMN2CHRNA7HRH3 | |
| SCHEMBL2907938 | 0.95 | CXCR4 (0.35) | CXCR4ALDH1A1SMN1; SMN2CHRNA7HRH3 | |
| SCHEMBL19593830 | 0.95 | ALDH1A1 (0.38) | CXCR4ALDH1A1SMN1; SMN2CHRNA7HRH3 | |
| SCHEMBL24606523 | 0.93 | CXCR4 (0.39) | CXCR4SMN1; SMN2CHRNA7HRH3CHRM5 | |
| Hydrochloric Acid SCHEMBL4430349 | 0.93 | CXCR4 (0.34) | CXCR4SMN1; SMN2CHRNA7HRH3CHRM5 | |
| Hydrochloric Acid SCHEMBL1169999 | 0.93 | CXCR4 (0.34) | CXCR4SMN1; SMN2CHRNA7HRH3CHRM5 | |
| SCHEMBL23586065 | 0.92 | ALDH1A1 (0.40) | CXCR4ALDH1A1SMN1; SMN2CHRNA7HRH3 | |
| SCHEMBL13509553 | 0.91 | CXCR4 (0.42) | CXCR4SMN1; SMN2HRH3CHRM5CHRM3 | |
| SCHEMBL25894882 | 0.90 | ALDH1A1 (0.45) | CXCR4ALDH1A1SMN1; SMN2CHRNA7HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| WO-2023109909-A1 | AROMATIC HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND USES THEREOF | 上海翊石医药科技有限公司 | 2023-06-22 | — | — | WO | disclosed |
| WO-2023007009-A1 | PYRAZOLOPYRIMIDINES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-02-02 | — | — | WO | disclosed |
| US-9783903-B2 | Additives for electroplating baths | ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) | 2017-10-10 | — | — | US | disclosed |
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| EP-2062879-A1 | Heterocyclic inhibitors of p38 | Vertex Pharmceuticals Incorporated (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7524847-B2 | Fused 1,3-dihydro-imidazole ring compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
| US-20090075981-A1 | INHIBITORS OF p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090075981-A1 | INHIBITORS OF p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-7423049-B2 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-09 | — | — | US | disclosed |
| US-20070219178-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR MULTIPLE SCLEROSIS | EISAI CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20070060572-A1 | Inhibitors of p38 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219178-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR MULTIPLE SCLEROSIS | MYT1, AQP4, AQP1 | CXCR4 183/4885ALDH1A1 1186/4885SMN1; SMN2 416/4885 |
| US-20090075981-A1 | INHIBITORS OF p38 | MAPK1, MAPK3, MAP3K1 | CXCR4 975/4885ALDH1A1 3189/4885SMN1; SMN2 2123/4885 |
| US-20230373983-A1 | AMIDO HETEROAROMATIC COMPOUNDS | CYP7A1, SLC10A1, CYP11B2 | CXCR4 4030/4885ALDH1A1 299/4885SMN1; SMN2 567/4885 |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | DPP4, HDAC1, DPP7 | CXCR4 178/4885ALDH1A1 686/4885SMN1; SMN2 3923/4885 |
| US-20070060572-A1 | Inhibitors of p38 | MAPK1, MAPK3, MAP3K1 | CXCR4 975/4885ALDH1A1 3189/4885SMN1; SMN2 2123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.